Abstract
Recent extension of the use of recombinant growth hormone (rhGH) to non-growth hormone-deficient patients necessitates close attention to possible complications in these patients, including effects on bone. Recent studies on the use of rhGH in children with chronic renal failure (CRF) provide some early data. No significant differences in radiographic osteodystrophy scores, serum calcium, phosphorus, or parathyroid hormone (PTH) levels were found between treated and untreated groups. Alkaline phosphatase increased transiently. The effect of renal osteodystrophy on growth response has not yet been reported. Animal models demonstrate that GH stimulates chondrocyte proliferation. Experimental data further suggest that GH can weaken the epiphyseal plate. Slipped capital femoral epiphysis has been reported in GH-deficient patients, before, during, and after GH therapy. In CRF patients treated with GH, slipped capital femoral epiphysis has also been reported. As renal osteodystrophy and hypocalcemia are risk factors for this condition, the relationship to GH therapy is unclear in these patients. Avascular necrosis, known to be associated with slipped capital femoral epiphysis and CRF, has also been reported in patients receiving GH, although the relationship to the therapy is unknown. Children with CRF treated with rhGH should be serially monitored for renal osteodystrophy, slipped capital femoral epiphysis, and avascular necrosis with serial radiographs and serum calcium, phosphorus, alkaline phosphatase, and PTH levels.
Similar content being viewed by others
References
Montini G (1995) Does rhGH treatment influence the course of renal osteodystrophy in children with CRI and is it a contraindication to rhGH treatment? Highlights 3:39–43
Ogle GD, Rosenberg AR, Kainer G (1992) Renal effects of growth hormone. II. Electrolyte homeostasis and body composition. Pediatr Nephrol 6:483–489
Fine RN, Yadin O, Moulton L, Nelson PA, Boechat MI, Lippe BM (1994) Five years experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 7:1–12
Hokken-Koelega ACS, Stijnen T, Keizer-Schrama SMPFD, Wit JM, Wolff ED, DeJong MCJW, Donckerwolcke RA, Abbad NCB, Bot A, Blum WF, Drop SLS (1991) Placebo-controlled, doubleblind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 338:585–590
Hokken-Koelega ACS, Stijnen T, DeJong MCJW, Donckerwolcke RA, Keizer-Schrama SMPFD, Blum WF, Drop SLS (1994) Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab 79:1185–1190
Tonshoff B, Dietz M, Haffner D, Tonshoff C, Stover B, Mehls O, and Members of the German Study Group for Growth Hormone Treatment and Chronic Renal Failure (1991) Effects of two years of growth hormone treatment in short children with renal disease. Acta Paediatr Scand 379:33–41
Mehls O, Broyer M on behalf of the European/Australian Study Group (1994) Growth response to recombinant human growth hormone in short prepubertal children with chronic renal failure with or without dialysis. Acta Paediatr Scand [Suppl] 399:81–87
Fine RN, Kohaut EC, Brown D, Perlman AJ, for the Genentech Cooperative Study Group (1994) Growth after recombinant human growth hormone treatment in children with chronic renal failure. J Pediatr 124:374–382
Zadik Z, Vaisman N, Lotan D, Vaisman E, Landau D, Blachar Y, Katz A, Drukker A (1992) Effect of growth hormone therapy on IGF-1, bone GLA-protein and bone mineral content in short children with and without chronic renal failure. Horm Res 38: 145–149
Watkins SL, Hogg RJ, Brewer ED, Powell DR, Boechat I, Attie K, Frane J, Brown D (1995) Bone mineral parameters in children with chronic renal failure receiving recombinant growth hormone therapy. A report of the Southwest Pediatric Nephrology Study Group (abstract). Pediatr Nephrol 9:C51
Deleted
Harris RW (1950) The endocrine basis for slipping of the upper femoral epiphysis. J Bone Joint Surg [Br] 31:5–11
Alexander CJ (1976) Effect of growth rate on the strength of the growth plate. Skeletal Radiol 1:67–76
Semple JC, Goldschmidt RG (1969) Epiphyseal maturation and slipping femoral epiphysis in a hypopituitary dwarf. Orthopedics 2:31–42
Rappaport EB, Fife D (1985) Slipped capital femoral epiphysis in growth hormone-deficient patients. Am J Dis Child 139:396–399
Prasad V, Greig F, Bastlan W, Castells S, Juan C, AvRuskin TW (1990) Slipped capital femoral epiphysis during treatment with recombinant growth hormone for isolated, partial growth hormone deficiency. J Pediatr 116:397–403
Mehls O, Ritz E, Krempien B, Gilli G, Link K, Willich E, Schärer K (1975) Slipped epiphyses in renal osteodystrophy. Arch Dis Child 50:545–554
Deleted
Catterall A, Roberts GC (1971) Association of Perthes' disease with congenital anomalies of genitourinary tract and inguinal region. Lancet I (707):996–997
Mehls O, Ritz E, Oppermann HC (1981) Femoral head necrosis in uremic children without steroid treatment or transplantation. J Pediatr 99:926–929
Watkins SL, Johanson A, Winters W, Avner ED (1990) Legg-Perthes in children with chronic renal failure during growth (abstract). J Am Soc Nephrol 1:344
Boechat MI, Watkins SL (1995) Avascular necrosis in children with chronic renal disease (abstract). Pediatr Radiol 25(8):676
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Watkins, S.L. Is severe renal osteodystrophy a contraindication for recombinant human growth hormone treatment?. Pediatr Nephrol 10, 351–354 (1996). https://doi.org/10.1007/BF00866781
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866781